![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PLCG2 |
Gene summary for PLCG2 |
![]() |
Gene information | Species | Human | Gene symbol | PLCG2 | Gene ID | 5336 |
Gene name | phospholipase C gamma 2 | |
Gene Alias | APLAID | |
Cytomap | 16q23.3 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P16885 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5336 | PLCG2 | GSM4909281 | Human | Breast | IDC | 1.27e-11 | -7.37e-01 | 0.21 |
5336 | PLCG2 | GSM4909282 | Human | Breast | IDC | 6.43e-05 | -6.33e-01 | -0.0288 |
5336 | PLCG2 | GSM4909285 | Human | Breast | IDC | 1.77e-06 | -7.08e-01 | 0.21 |
5336 | PLCG2 | GSM4909286 | Human | Breast | IDC | 2.70e-11 | -7.24e-01 | 0.1081 |
5336 | PLCG2 | GSM4909290 | Human | Breast | IDC | 4.02e-03 | -6.25e-01 | 0.2096 |
5336 | PLCG2 | GSM4909291 | Human | Breast | IDC | 7.46e-05 | -7.18e-01 | 0.1753 |
5336 | PLCG2 | GSM4909293 | Human | Breast | IDC | 2.29e-10 | -4.40e-01 | 0.1581 |
5336 | PLCG2 | GSM4909294 | Human | Breast | IDC | 3.75e-02 | -5.17e-01 | 0.2022 |
5336 | PLCG2 | GSM4909297 | Human | Breast | IDC | 1.35e-08 | -6.76e-01 | 0.1517 |
5336 | PLCG2 | GSM4909298 | Human | Breast | IDC | 4.73e-11 | -7.27e-01 | 0.1551 |
5336 | PLCG2 | GSM4909299 | Human | Breast | IDC | 1.60e-06 | -6.56e-01 | 0.035 |
5336 | PLCG2 | GSM4909301 | Human | Breast | IDC | 2.38e-03 | -5.93e-01 | 0.1577 |
5336 | PLCG2 | GSM4909302 | Human | Breast | IDC | 3.54e-08 | -6.85e-01 | 0.1545 |
5336 | PLCG2 | GSM4909304 | Human | Breast | IDC | 1.46e-05 | -6.03e-01 | 0.1636 |
5336 | PLCG2 | GSM4909305 | Human | Breast | IDC | 8.81e-04 | -6.58e-01 | 0.0436 |
5336 | PLCG2 | GSM4909306 | Human | Breast | IDC | 1.31e-09 | -7.19e-01 | 0.1564 |
5336 | PLCG2 | GSM4909307 | Human | Breast | IDC | 2.38e-08 | -7.11e-01 | 0.1569 |
5336 | PLCG2 | GSM4909308 | Human | Breast | IDC | 2.44e-09 | -7.29e-01 | 0.158 |
5336 | PLCG2 | GSM4909311 | Human | Breast | IDC | 4.61e-06 | -6.01e-01 | 0.1534 |
5336 | PLCG2 | GSM4909312 | Human | Breast | IDC | 1.66e-11 | -7.39e-01 | 0.1552 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00100389 | Breast | Precancer | response to metal ion | 47/1080 | 373/18723 | 3.88e-07 | 1.79e-05 | 47 |
GO:00432549 | Breast | Precancer | regulation of protein-containing complex assembly | 50/1080 | 428/18723 | 1.63e-06 | 5.97e-05 | 50 |
GO:00313349 | Breast | Precancer | positive regulation of protein-containing complex assembly | 33/1080 | 237/18723 | 2.39e-06 | 8.21e-05 | 33 |
GO:00018196 | Breast | Precancer | positive regulation of cytokine production | 52/1080 | 467/18723 | 4.18e-06 | 1.29e-04 | 52 |
GO:00420609 | Breast | Precancer | wound healing | 48/1080 | 422/18723 | 5.48e-06 | 1.63e-04 | 48 |
GO:00512358 | Breast | Precancer | maintenance of location | 40/1080 | 327/18723 | 5.85e-06 | 1.71e-04 | 40 |
GO:00516519 | Breast | Precancer | maintenance of location in cell | 30/1080 | 214/18723 | 5.91e-06 | 1.71e-04 | 30 |
GO:00022378 | Breast | Precancer | response to molecule of bacterial origin | 43/1080 | 363/18723 | 6.05e-06 | 1.72e-04 | 43 |
GO:00507293 | Breast | Precancer | positive regulation of inflammatory response | 23/1080 | 142/18723 | 6.51e-06 | 1.81e-04 | 23 |
GO:00324968 | Breast | Precancer | response to lipopolysaccharide | 41/1080 | 343/18723 | 7.94e-06 | 2.17e-04 | 41 |
GO:0050727 | Breast | Precancer | regulation of inflammatory response | 44/1080 | 386/18723 | 1.26e-05 | 3.22e-04 | 44 |
GO:00106348 | Breast | Precancer | positive regulation of epithelial cell migration | 25/1080 | 176/18723 | 2.75e-05 | 6.21e-04 | 25 |
GO:00321034 | Breast | Precancer | positive regulation of response to external stimulus | 46/1080 | 427/18723 | 3.41e-05 | 7.40e-04 | 46 |
GO:00106319 | Breast | Precancer | epithelial cell migration | 40/1080 | 357/18723 | 4.57e-05 | 9.71e-04 | 40 |
GO:00725938 | Breast | Precancer | reactive oxygen species metabolic process | 30/1080 | 239/18723 | 5.13e-05 | 1.07e-03 | 30 |
GO:00901329 | Breast | Precancer | epithelium migration | 40/1080 | 360/18723 | 5.51e-05 | 1.14e-03 | 40 |
GO:00313493 | Breast | Precancer | positive regulation of defense response | 33/1080 | 278/18723 | 6.79e-05 | 1.36e-03 | 33 |
GO:00901309 | Breast | Precancer | tissue migration | 40/1080 | 365/18723 | 7.48e-05 | 1.47e-03 | 40 |
GO:00508789 | Breast | Precancer | regulation of body fluid levels | 40/1080 | 379/18723 | 1.68e-04 | 2.77e-03 | 40 |
GO:00106329 | Breast | Precancer | regulation of epithelial cell migration | 33/1080 | 292/18723 | 1.74e-04 | 2.86e-03 | 33 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0513118 | Breast | Precancer | Shigellosis | 44/684 | 247/8465 | 3.91e-07 | 6.86e-06 | 5.26e-06 | 44 |
hsa0516718 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0516918 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0406616 | Breast | Precancer | HIF-1 signaling pathway | 23/684 | 109/8465 | 1.51e-05 | 1.59e-04 | 1.22e-04 | 23 |
hsa0511014 | Breast | Precancer | Vibrio cholerae infection | 14/684 | 50/8465 | 2.67e-05 | 2.64e-04 | 2.02e-04 | 14 |
hsa0467018 | Breast | Precancer | Leukocyte transendothelial migration | 20/684 | 114/8465 | 7.26e-04 | 5.33e-03 | 4.09e-03 | 20 |
hsa0520514 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0513119 | Breast | Precancer | Shigellosis | 44/684 | 247/8465 | 3.91e-07 | 6.86e-06 | 5.26e-06 | 44 |
hsa0516719 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0516919 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0406617 | Breast | Precancer | HIF-1 signaling pathway | 23/684 | 109/8465 | 1.51e-05 | 1.59e-04 | 1.22e-04 | 23 |
hsa0511015 | Breast | Precancer | Vibrio cholerae infection | 14/684 | 50/8465 | 2.67e-05 | 2.64e-04 | 2.02e-04 | 14 |
hsa0467019 | Breast | Precancer | Leukocyte transendothelial migration | 20/684 | 114/8465 | 7.26e-04 | 5.33e-03 | 4.09e-03 | 20 |
hsa0520515 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0516922 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0511022 | Breast | IDC | Vibrio cholerae infection | 17/867 | 50/8465 | 4.82e-06 | 6.82e-05 | 5.10e-05 | 17 |
hsa0520523 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLCG2 | SNV | Missense_Mutation | c.2129N>C | p.Phe710Ser | p.F710S | P16885 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BR-8589-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
PLCG2 | SNV | Missense_Mutation | c.1269A>C | p.Glu423Asp | p.E423D | P16885 | protein_coding | tolerated(0.55) | benign(0.007) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
PLCG2 | SNV | Missense_Mutation | c.1793A>C | p.Lys598Thr | p.K598T | P16885 | protein_coding | deleterious(0.03) | possibly_damaging(0.557) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
PLCG2 | SNV | Missense_Mutation | c.819T>G | p.Ile273Met | p.I273M | P16885 | protein_coding | tolerated(0.07) | possibly_damaging(0.776) | TCGA-BR-A4PD-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PLCG2 | SNV | Missense_Mutation | c.134N>C | p.Val45Ala | p.V45A | P16885 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
PLCG2 | SNV | Missense_Mutation | c.1882N>A | p.Glu628Lys | p.E628K | P16885 | protein_coding | tolerated(0.11) | benign(0.14) | TCGA-CG-5726-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PLCG2 | SNV | Missense_Mutation | c.2567N>C | p.Asn856Thr | p.N856T | P16885 | protein_coding | tolerated(0.4) | benign(0.057) | TCGA-F1-A448-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR | |
PLCG2 | SNV | Missense_Mutation | novel | c.2604C>A | p.Asn868Lys | p.N868K | P16885 | protein_coding | tolerated(0.08) | benign(0.205) | TCGA-IN-A6RL-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
PLCG2 | SNV | Missense_Mutation | novel | c.2212N>A | p.Glu738Lys | p.E738K | P16885 | protein_coding | tolerated(0.07) | probably_damaging(0.991) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
PLCG2 | SNV | Missense_Mutation | novel | c.3031N>A | p.Ala1011Thr | p.A1011T | P16885 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VQ-A8PP-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5336 | PLCG2 | DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE, PHOSPHOLIPASE | inhibitor | 252827477 | ||
5336 | PLCG2 | DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE, PHOSPHOLIPASE | IBRUTINIB | IBRUTINIB | 24869598 |
Page: 1 |